Table 4.
Outcomes from studies investigating effects of neoadjuvant ADT and outcomes of patients with localized prostate cancer.
| References | N | Pca Staging | ADT Use | Comparison | Outcome |
|---|---|---|---|---|---|
| [149] | 7538 | T1–T3 | Neo | ADT vs. surgery or radiation | ADT increases hazard ratio |
| [150] | 19,271 | T1–T2 | Neo (<180 days) | ADT vs. conservative management | Decreased PCSS |
| [151] | 16,000 | T1–T2 | Neo (<first 6 months) | ADT in first 6months vs. no ADT in first 6 months | Increased PCSM |
| [153] | 29,775 | Localized | Neo | ADT vs. noADT | ADT increases need for subsequent treatments |
| [158] | 844 | Neo (<first 6 months) | Neo compared to WW, RP, radiotherapy | Neo had worse 10 year PCSS of all treatments | |
| [159] | 10,179 | Localised | Neo | Neo compared to no treatment, RP, BT, ERBT | ADT worse PCSS |
| [160] | 402 | Localised | Neo (<first 3 months) | Neo compared to RP alone | Neo = pathological downstaging and lowers % of patients with positive margins |
| [161] | 547 | Localised | Neo | 3-month vs. 8-month neo | Positive margin rates were significantly lower in the 8 than 3-month group |
| [162] | 167 | T1a–T2b | Neo (<first 3 months) | 3-month neo vs. RP alone | Neo had less lymph node involvement, less positive margins |
| [163] | 393 | T2–T3 | Neo (3–6 months) | Neo vs. RP alone | Neo had better positive margin rates |
| [164] | 119 | T2–T3a | Neo (<first 4 months) | 4-month neo vs. RP alone | Neo had better positive margin rates |
| [154] | 176 | B2/T2–T3 | Neo | 1-year ADT vs. long term ADT | No measurable significant benefit |
| [155] | 57 | Neo | No benefit | ||
| [156] | 1006 | Low-intermediate | Neo ADT + LDB | ADT prior to or after LDB | No effect of PCSS |
| [165] | 282 | T2b | Neo (<first 3 months) | 3-month neo vs. RP alone | No difference in 5 year BCR |
| [166] | 126 | T1b–T3aNXM0 | Neo (<first 3 months) | 3-month neo vs. RP alone | No difference in PSA progression-free survival (7 year follow up) |
| [167] | 148 | T1b–T3 | Neo (<first 3 months) | 3-month neo vs. RP alone | No significant difference in BCR-free (8 year followup) |
| [152] | 985 | Localized | ADT Immediately or upon symptoms of progression | Immediate ADT vs. delayed ADT | Delayed ADT increased risk of mortality |
| [157] | 1903 | T1–T2 | Neo (diethylstilbesterol) | ADT in T1 vs. ADT in T2 | benefit T2, deletrious in T1 |
| [168] | 213 | T1b/c–T2c | Neo | Neo prior to surgery vs. surgery alone | Neo = less organ confinement, lower 7-year survival |